InsidersTradesSigma
Follow the Adaptive Biotechnologies Corporation stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares trade on US US, under the oversight of SEC (Form 4). The latest transaction was disclosed on 2 July 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: SUSAN BOBULSKY. The full history is accessible without an account.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
7 of 7 declarations
Adaptive Biotechnologies Corporation is a company focused on developing DNA sequencing technologies for the diagnosis and treatment of diseases. It primarily concentrates on applications in immunology and oncology.